KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Cash from Financing Activities (2017 - 2025)

Elanco Animal Health (ELAN) has disclosed Cash from Financing Activities for 9 consecutive years, with -$18.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 43.75% to -$18.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$275.0 million through Dec 2025, up 81.57% year-over-year, with the annual reading at -$275.0 million for FY2025, 81.57% up from the prior year.
  • Cash from Financing Activities hit -$18.0 million in Q4 2025 for Elanco Animal Health, up from -$153.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $231.0 million in Q3 2021 to a low of -$1.3 billion in Q3 2024.
  • Historically, Cash from Financing Activities has averaged -$109.4 million across 5 years, with a median of -$75.5 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 344.44% in 2021 and later tumbled 10100.0% in 2022.
  • Year by year, Cash from Financing Activities stood at $44.0 million in 2021, then plummeted by 290.91% to -$84.0 million in 2022, then crashed by 65.48% to -$139.0 million in 2023, then skyrocketed by 76.98% to -$32.0 million in 2024, then skyrocketed by 43.75% to -$18.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ELAN at -$18.0 million in Q4 2025, -$153.0 million in Q3 2025, and -$156.0 million in Q2 2025.